+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Meningococcal Vaccines Market by Type, Category, Dosage Type, Target Group, End-User - Global Forecast 2025-2030- Product Image
Meningococcal Vaccines Market by Type, Category, Dosage Type, Target Group, End-User - Global Forecast 2025-2030- Product Image
Sale

Meningococcal Vaccines Market by Type, Category, Dosage Type, Target Group, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 185 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 4857895
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Meningococcal Vaccines Market grew from USD 5.45 billion in 2023 to USD 5.95 billion in 2024. It is expected to continue growing at a CAGR of 10.50%, reaching USD 10.97 billion by 2030.

The scope of the meningococcal vaccines market encompasses the development, production, and distribution of vaccines designed to protect against Neisseria meningitidis, a bacterium responsible for serious infections like meningitis and septicemia. These vaccines are critical for public health, particularly in age groups and regions with high incidence rates. Their necessity stems from the often severe and rapid progression of meningococcal infections, which can lead to substantial morbidity and mortality. Applications span from routine immunization programs in infants and adolescents to targeted vaccinations in outbreak scenarios and among travelers. End-users primarily include government health bodies, private healthcare facilities, and research institutions.

Market growth is buoyed by rising awareness of meningococcal diseases, government immunization initiatives, and the introduction of advanced vaccines such as conjugate and multicomponent vaccines. Increasing global travel and migration further drive demand for vaccinations. However, the market faces challenges including high vaccine costs, limited access in low-income regions, and potential side effects, deterring uptake. Stringent regulatory requirements also pose significant hurdles for new vaccine approvals.

To capitalize on opportunities, companies should focus on innovation aimed at developing broader-spectrum and more affordable vaccines. Collaborations with healthcare providers to enhance distribution channels and educational campaigns to increase public awareness about the importance of vaccination could also be beneficial. Moreover, enhancing vaccine storage and transport logistics, especially in underdeveloped regions, will expand reach.

Key areas for research and innovation include improving vaccine strain coverage to respond to changing epidemiological patterns, creating needle-free delivery systems for enhanced safety and acceptance, and developing more efficient manufacturing processes to reduce costs. The meningococcal vaccine market is dynamic, characterized by ongoing scientific advancements and the need for adaptable strategies to navigate regulatory landscapes and respond to emerging infectious threats. Addressing these factors with strategic initiatives can position businesses effectively within this vital healthcare sector.

Understanding Market Dynamics in the Meningococcal Vaccines Market

The Meningococcal Vaccines Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing Incidence of Meningitis Across the World
    • Rising R&D Activities and Vaccines Developments in the Pipeline
    • Rising Immunization Programs and Government Initiatives for Meningococcal Diseases
  • Market Restraints
    • High Cost of Meningococcal Vaccines Production
  • Market Opportunities
    • Incidence of Bacterial Meningitis in Emerging Countries Coupled with Improvement in Surveillance System
    • Elevation of Collaborations and Partnerships to Support the Development of the Vaccines
  • Market Challenges
    • Limitations and Side Effects Associated with Meningococcal Vaccines

Exploring Porter’s Five Forces for the Meningococcal Vaccines Market

Porter’s Five Forces framework further strengthens the insights of the Meningococcal Vaccines Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Meningococcal Vaccines Market

External macro-environmental factors deeply influence the performance of the Meningococcal Vaccines Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Meningococcal Vaccines Market

The Meningococcal Vaccines Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Meningococcal Vaccines Market

The Meningococcal Vaccines Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Meningococcal Vaccines Market

The Meningococcal Vaccines Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Meningococcal Vaccines Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Bio-Manguinhos, Bio-Med (P) Limited, CanSino Biologics Inc., Chongqing Zhifei Biological Products Co., Ltd., Emergent BioSolutions Inc., GlaxoSmithKline PLC, Incepta Pharmaceuticals Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Nanolek, LLC, Novartis AG, Panacea Biotec Ltd., Petrovax Pharm, Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Sinovac Biotech Ltd., SK bioscience, Taj Pharmaceuticals Limited, Vabiotech, and Walvax Biotechnology Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Meningococcal Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Combination Vaccines
      • MenHibrix
      • Menitorix
    • Conjugate Vaccines
      • Menactra
      • MenAfriVac
      • Meningitec
      • Menjugate
      • Menveo
      • NeisVac-C
      • Nimenrix
      • NmVac4-DT
    • Men B Vaccines
      • Bexsero
      • Trumenba
    • Polysaccharide Vaccines
      • Mencevax
      • Menomune
      • NmVac4
  • Category
    • Intramuscular
    • Subcutaneous
  • Dosage Type
    • Booster Vaccination
    • Primary Vaccination
  • Target Group
    • Adult
    • Preteen
    • Teenager
  • End-User
    • Hospital Pharmacies
    • Pediatric Clinic
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Meningococcal Vaccines Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Incidence of Meningitis Across the World
5.1.1.2. Rising R&D Activities and Vaccines Developments in the Pipeline
5.1.1.3. Rising Immunization Programs and Government Initiatives for Meningococcal Diseases
5.1.2. Restraints
5.1.2.1. High Cost of Meningococcal Vaccines Production
5.1.3. Opportunities
5.1.3.1. Incidence of Bacterial Meningitis in Emerging Countries Coupled with Improvement in Surveillance System
5.1.3.2. Elevation of Collaborations and Partnerships to Support the Development of the Vaccines
5.1.4. Challenges
5.1.4.1. Limitations and Side Effects Associated with Meningococcal Vaccines
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Meningococcal Vaccines Market, by Type
6.1. Introduction
6.2. Combination Vaccines
6.3.1. MenHibrix
6.3.2. Menitorix
6.3. Conjugate Vaccines
6.4.1. Menactra
6.4.2. MenAfriVac
6.4.3. Meningitec
6.4.4. Menjugate
6.4.5. Menveo
6.4.6. NeisVac-C
6.4.7. Nimenrix
6.4.8. NmVac4-DT
6.4. Men B Vaccines
6.5.1. Bexsero
6.5.2. Trumenba
6.5. Polysaccharide Vaccines
6.6.1. Mencevax
6.6.2. Menomune
6.6.3. NmVac4
7. Meningococcal Vaccines Market, by Category
7.1. Introduction
7.2. Intramuscular
7.3. Subcutaneous
8. Meningococcal Vaccines Market, by Dosage Type
8.1. Introduction
8.2. Booster Vaccination
8.3. Primary Vaccination
9. Meningococcal Vaccines Market, by Target Group
9.1. Introduction
9.2. Adult
9.3. Preteen
9.4. Teenager
10. Meningococcal Vaccines Market, by End-User
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Pediatric Clinic
10.4. Retail Pharmacies
11. Americas Meningococcal Vaccines Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Meningococcal Vaccines Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Meningococcal Vaccines Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Astellas Pharma Inc.
15.1.2. AstraZeneca PLC
15.1.3. Bavarian Nordic A/S
15.1.4. Bharat Biotech Ltd.
15.1.5. Bio-Manguinhos
15.1.6. Bio-Med (P) Limited
15.1.7. CanSino Biologics Inc.
15.1.8. Chongqing Zhifei Biological Products Co., Ltd.
15.1.9. Emergent BioSolutions Inc.
15.1.10. GlaxoSmithKline PLC
15.1.11. Incepta Pharmaceuticals Ltd.
15.1.12. Merck & Co., Inc.
15.1.13. Mitsubishi Tanabe Pharma Corporation
15.1.14. Nanolek, LLC
15.1.15. Novartis AG
15.1.16. Panacea Biotec Ltd.
15.1.17. Petrovax Pharm
15.1.18. Pfizer Inc.
15.1.19. Sanofi S.A.
15.1.20. Serum Institute of India Pvt. Ltd.
15.1.21. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
15.1.22. Sinovac Biotech Ltd.
15.1.23. SK bioscience
15.1.24. Taj Pharmaceuticals Limited
15.1.25. Vabiotech
15.1.26. Walvax Biotechnology Co., Ltd.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
List of Figures
FIGURE 1. MENINGOCOCCAL VACCINES MARKET RESEARCH PROCESS
FIGURE 2. MENINGOCOCCAL VACCINES MARKET SIZE, 2023 VS 2030
FIGURE 3. MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MENINGOCOCCAL VACCINES MARKET DYNAMICS
FIGURE 7. MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2030 (%)
FIGURE 10. MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2023 VS 2030 (%)
FIGURE 12. MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2023 VS 2030 (%)
FIGURE 14. MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 16. MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. MENINGOCOCCAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. MENINGOCOCCAL VACCINES MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. MENINGOCOCCAL VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 8. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENHIBRIX, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENITORIX, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 12. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENACTRA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENAFRIVAC, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENINGITEC, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENJUGATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENVEO, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. MENINGOCOCCAL VACCINES MARKET SIZE, BY NEISVAC-C, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. MENINGOCOCCAL VACCINES MARKET SIZE, BY NIMENRIX, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. MENINGOCOCCAL VACCINES MARKET SIZE, BY NMVAC4-DT, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 22. MENINGOCOCCAL VACCINES MARKET SIZE, BY BEXSERO, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. MENINGOCOCCAL VACCINES MARKET SIZE, BY TRUMENBA, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 26. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENCEVAX, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENOMUNE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. MENINGOCOCCAL VACCINES MARKET SIZE, BY NMVAC4, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 30. MENINGOCOCCAL VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. MENINGOCOCCAL VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 33. MENINGOCOCCAL VACCINES MARKET SIZE, BY BOOSTER VACCINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. MENINGOCOCCAL VACCINES MARKET SIZE, BY PRIMARY VACCINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 36. MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. MENINGOCOCCAL VACCINES MARKET SIZE, BY PRETEEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. MENINGOCOCCAL VACCINES MARKET SIZE, BY TEENAGER, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 73. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 74. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 75. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 76. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 77. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 78. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 79. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 81. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 82. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 83. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 84. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 85. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 86. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 87. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 88. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 102. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 104. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 105. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 109. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 111. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 112. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 113. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 114. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 115. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 116. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 117. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 120. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 121. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 122. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 123. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 124. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 125. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 126. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 128. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 129. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 130. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 131. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 132. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 133. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 134. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 135. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 138. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 139. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 140. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 141. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 142. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 143. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 144. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 146. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 147. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 148. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 149. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 150. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 151. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 152. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 153. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 155. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 156. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 157. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 158. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 159. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 160. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 161. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 162. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 164. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 165. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 166. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 167. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 168. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 169. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 170. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 171. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 173. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 174. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 175. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 176. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 177. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 178. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 179. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 180. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 182. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 183. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 184. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 185. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 186. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 187. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 188. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 189. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 191. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 192. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 193. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 194. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 195. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 196. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 197. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 198. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 200. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 201. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 202. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 203. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 204. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 205. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 206. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 207. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 208. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 209. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 210. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 211. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 212. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 213. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 214. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 215. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 216. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 227. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 228. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 229. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 230. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 231. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 232. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 233. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 234. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 235. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 236. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 237. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 238. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 239. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 240. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 241. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 242. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 243. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 244. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 245. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 246. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 247. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 248. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 249. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 250. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 251. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 252. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 253. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 254. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 255. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 256. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 257. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 258. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 259. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 260. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 261. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 262. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 263. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 264. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 265. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 266. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 267. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 268. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 269. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 270. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 271. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 274. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 275. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 276. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 277. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 278. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 279. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 280. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 281. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 282. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 283. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 284. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 285. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 286. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 287. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 288. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 289. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 295. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 296. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 297. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 298. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 299. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 300. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 301. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 302. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 303. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 304. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 305. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 306. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 307. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 308. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 309. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 310. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 311. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 312. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 313. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 314. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 315. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 316. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 317. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 318. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 319. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 320. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 321. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 322. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 323. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 324. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 325. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 326. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 327. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 328. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 329. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
TABLE 330. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
TABLE 331. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 332. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
TABLE 333. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
TABLE 334. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 335. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 336. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
TABLE 337. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGA

Companies Mentioned

The leading players in the Meningococcal Vaccines Market, which are profiled in this report, include:
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech Ltd.
  • Bio-Manguinhos
  • Bio-Med (P) Limited
  • CanSino Biologics Inc.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • Incepta Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Nanolek, LLC
  • Novartis AG
  • Panacea Biotec Ltd.
  • Petrovax Pharm
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Sinovac Biotech Ltd.
  • SK bioscience
  • Taj Pharmaceuticals Limited
  • Vabiotech
  • Walvax Biotechnology Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages185
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.95 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.97 Billion
Compound Annual Growth Rate10.5%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Meningococcal Vaccines Market Report by Vaccine Type, Composition, Vaccine Serotype, Distribution Channel, End User, and Region 2024-2032 - Product Image

Meningococcal Vaccines Market Report by Vaccine Type, Composition, Vaccine Serotype, Distribution Channel, End User, and Region 2024-2032

  • Report
  • 137 Pages
  • Global
From
Meningococcal Vaccines Market Report 2025 - Product Image

Meningococcal Vaccines Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Meningococcal Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Meningococcal Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
Meningococcal Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Meningococcal Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Meningococcal Vaccines Market Report and Forecast 2024-2032 - Product Image

Meningococcal Vaccines Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From

About the Meningococcal Vaccine Market

The Meningococcal Vaccine is a type of vaccine used to protect against meningococcal disease, a serious and potentially fatal infection caused by the bacterium Neisseria meningitidis. It is recommended for adolescents and young adults, as well as for those at increased risk of infection, such as travelers to certain countries and those with certain medical conditions. The vaccine is available in both conjugate and polysaccharide forms, and is typically administered in two or three doses. The Meningococcal Vaccine market is part of the larger Infectious Diseases Drugs market, which includes a range of treatments for various infectious diseases. The Meningococcal Vaccine market is expected to grow in the coming years, driven by increasing awareness of the disease and the availability of new vaccines. Some companies in the Meningococcal Vaccine market include GlaxoSmithKline, Merck, Pfizer, Sanofi, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.